Cancer genomics firm Tempus' pact with Cleveland's UH Seidman Cancer Center adds to its list of partnerships with academic oncology centers.
FDA clearance of the first NGS companion diagnostic paves the way for other comprehensive genomic profiling tests, but Foundation will have to educate docs on the benefits of its test.
University of Cambridge researchers found that the portion of tumor DNA in patients' blood could predict treatment response and time to disease progression.
The test is approved to identify patients who harbor BRCA mutations and are therefore more likely to respond to Clovis Oncology's ovarian cancer drug Rubraca.
Philips plans to offer the software as a module in its IntelliSpace Genomics platform, which is used for integrating and analyzing genomic and phenotypic data.
Myriad filed the first PMA module with the FDA, though based on the agency's feedback it's unclear whether it will view myChoice HRD as a companion or complementary test.
In phase two of a program started last year, 30-year-old women and men in five Alabama counties will be able to get an NGS-based cancer screening test for free over the next year.
The database is intended to provide the research community with a resource of control cases to aid in the evaluation of variants of unknown significance in breast cancer.
In PNAS this week: mutation patterns in uterine and ovarian carcinosarcomas, deep genome sequences, and more.
The study showed an overall benefit regardless of BRCA mutation or HRD status, but some analysts believe the FDA still might require a CDx for niraparib.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.